Depemokimab Antibody is a research-grade biosimilar monoclonal antibody targeting IL5. It is a humanized IgG1-Kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Interleukin-5 (IL5) is a ~15 kDa protein. Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils. Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation. Mechanistically, exerts its biological effects through a receptor composed of IL5RA subunit and the cytokine receptor common subunit beta/CSF2RB. Binding to the receptor leads to activation of various kinases including LYN, SYK and JAK2 and thereby propagates signals through the RAS-MAPK and JAK-STAT5 pathways respectively. IL5 is the therapeutic target of mepolizumab (Nucala).
Product Name:
Depemokimab Antibody
SKU:
GXBS00671
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
IL5
Isotype:
IgG1-Kappa
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FACS, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
GSK-3511294, 2243274-14-6
Purity:
>95% purity as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
